DCT
L-dopachrome tautomerase
Also known as: TRP-2, TRP2, TYRP2, TYRP2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P40126
- Gene
- DCT
- Ensembl
- ENSG00000080166
- Chromosome
- 13
- Canonical length
- 519 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
- Subcellular location
- Vesicles,Plasma membrane
OverviewNCBI Gene
Predicted to enable dopachrome isomerase activity. Involved in response to blue light. Located in intracellular membrane-bounded organelle and plasma membrane. Implicated in oculocutaneous albinism. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
519 residues, UniProt reviewed canonical sequence.
>P40126|DCT
1 MSPLWWGFLL SCLGCKILPG AQGQFPRVCM TVDSLVNKEC CPRLGAESAN VCGSQQGRGQ
61 CTEVRADTRP WSGPYILRNQ DDRELWPRKF FHRTCKCTGN FAGYNCGDCK FGWTGPNCER
121 KKPPVIRQNI HSLSPQEREQ FLGALDLAKK RVHPDYVITT QHWLGLLGPN GTQPQFANCS
181 VYDFFVWLHY YSVRDTLLGP GRPYRAIDFS HQGPAFVTWH RYHLLCLERD LQRLIGNESF
241 ALPYWNFATG RNECDVCTDQ LFGAARPDDP TLISRNSRFS SWETVCDSLD DYNHLVTLCN
301 GTYEGLLRRN QMGRNSMKLP TLKDIRDCLS LQKFDNPPFF QNSTFSFRNA LEGFDKADGT
361 LDSQVMSLHN LVHSFLNGTN ALPHSAANDP IFVVLHSFTD AIFDEWMKRF NPPADAWPQE
421 LAPIGHNRMY NMVPFFPPVT NEELFLTSDQ LGYSYAIDLP VSVEETPGWP TTLLVVMGTL
481 VALVGLFVLL AFLQYRRLRK GYTPLMETHL SSKRYTEEALocalizationUniProt · AlphaFold · HPA
Whether an antibody against DCT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 102 nTPM
Expression across tissuesHPA
Tissue
- skin: 102 nTPM
- breast: 2.8 nTPM
- pituitary gland: 1.5 nTPM
- basal ganglia: 1.4 nTPM
- salivary gland: 1.3 nTPM
- epididymis: 0.9 nTPM
Single-cell type
- melanocytes: 9,102 nCPM
- basal keratinocytes: 100 nCPM
- corticotrophs: 42 nCPM
- late spermatids: 41 nCPM
- oligodendrocytes: 26 nCPM
- early spermatids: 23 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- basal ganglia: 2.2 nTPM
- cerebral cortex: 1.7 nTPM
- hypothalamus: 1.6 nTPM
- amygdala: 1.5 nTPM
- midbrain: 1.5 nTPM
- medulla oblongata: 1.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DCT.
Disease | AllUniProt
Conditions DCT is implicated in, by any mechanism.
- Albinism, oculocutaneous, 8 (OCA8) MIM:619165
Disease | GeneticClinVar
11 pathogenic / likely-pathogenic of 98 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Oculocutaneous albinism type 8
- Albinism
Disease | ImmuneIEDB
Conditions an epitope on DCT was assayed in.
- melanoma T cell
- skin melanoma T cell
- glioblastoma T cell
ReferencesPubMed · IEDB
Publications for DCT from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
1998 · J Invest Dermatol · RCR 2.5 · 99 citations - Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).
1997 · Clin Exp Immunol · RCR 1.7 · 62 citations - Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue.
2002 · Cancer Immun · RCR 0.2 · 9 citations
Reference: T cellIEDB
6 publications
- TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
2023 · J Immunother Cancer · RCR 1 · 12 citations - Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
2020 · Front Immunol · RCR 0.7 · 19 citations - Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.
2022 · Clin Cancer Res · RCR 0.6 · 10 citations - Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
2020 · Elife · RCR 0.6 · 17 citations - Broadening the repertoire of melanoma-associated T-cell epitopes.
2015 · Cancer Immunol Immunother · RCR 0.2 · 9 citations
Show 1 more
- Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
2022 · Front Immunol · RCR 0.2 · 3 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.17
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.35
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell development
- developmental pigmentation
- epidermis development
- melanin biosynthetic process from tyrosine
- positive regulation of neuroblast proliferation
- response to blue light
- ventricular zone neuroblast division
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DCT as an antibody target. Whether an autoantibody or antibody against DCT could matter depends on whether native DCT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DCT is annotated at the cell surface, where native DCT is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label DCT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...